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a b s t r a c t
Modulation of metabotropic glutamate 2 (mGlu2) receptor function has huge potential for treating
psychiatric and neurological diseases. Development of drugs acting on mGlu2 receptors depends on
the development and use of translatable animal models of disease. We report here a stop codon
mutation at cysteine 407 in Grm2 (cys407*) that is common in some Wistar rats. Therefore, researchers
in this ﬁeld need to be aware of strains with this mutation. Our genotypic survey found widespread
prevalence of the mutation in commercial Wistar strains, particularly those known as Han Wistar. Such
Han Wistar rats are ideal for research into the separate roles of mGlu2 and mGlu3 receptors in CNS
function. Previous investigations, unknowingly using such mGlu2 receptor-lacking rats, provide in-
sights into the role of mGlu2 receptors in behaviour. The Grm2 mutant rats, which dominate some
selectively bred lines, display characteristics of altered emotionality, impulsivity and risk-related be-
haviours and increased voluntary alcohol intake compared with their mGlu2 receptor-competent
counterparts. In addition, the data further emphasize the potential therapeutic role of mGlu2 re-
ceptors in psychiatric and neurological disease, and indicate novel methods of studying the role of
mGlu2 and mGlu3 receptors.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Abbreviations: mGlu2 receptor, metabotropic glutamate receptor 2; RGD, Rat
Genomic Database.
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1. Introduction
The metabotropic glutamate 2 (mGlu2) receptor belongs to the
family of G-protein coupled glutamate receptors that modulate
transmission at synapses throughout the mammalian central
nervous system, and that have been proposed as major targets for
the development of drugs for human psychiatric and neurological
diseases (Niswender and Conn, 2010; Nicoletti et al., 2011; Chaki
et al., 2013; Li et al., 2015). The mGlu2 receptors signal through
Gai/o proteins inhibiting adenyl cyclase and reducing cAMP
(Tanabe et al., 1992), cascading into effects on multiple systems
including PKA/MAPK, GSK-3b, Src kinase, AMPA and NMDA re-
ceptors etc (Pin and Duvoisin, 1995; Harris et al., 2004; Trepanier
et al., 2013; Wang et al., 2013). They also signal through Gb/g
inhibiting calcium channels (Chavis et al., 1994; Scanziani et al.,
1995) and activating potassium channels (Knoﬂach and Kemp,
1998; Chavez-Noriega et al., 2002). The major established physi-
ological function of mGlu2 receptors is to modulate synaptic
transmission as presynaptic auto- and hetero-receptors at gluta-
matergic and GABA-ergic terminals (Battaglia et al., 1997;
Cartmell and Schoepp, 2000; Smolders et al., 2004). The peri-
synaptic location of mGlu2 receptors ideally positions them for
sensing glutamate overﬂow (Petralia et al., 1996; Shigemoto et al.,
1997) and release from astrocytes (Moran et al., 2005; Kalivas,
2009).
Such complexity of the actions of a single receptor subtype
confounds attempts at predicting effects of exogenous agonists or
antagonists of mGlu2 receptor on whole animal behaviours and
hence their therapeutic potential. Nevertheless the predicted
potential for mGlu2/3 receptor agonists based on limiting gluta-
mate release has been borne out in animal models of schizo-
phrenia (Schoepp and Marek, 2002), anxiety (Helton et al., 1998;
Swanson et al., 2005), cerebral ischaemia (Bruno et al., 2001),
epilepsy (Smolders et al., 2004), drug addiction (Kalivas, 2009)
and chronic pain (Chiechio et al., 2010). There has also been some
limited success with clinical studies (Grillon et al., 2003; Patil
et al., 2007; Dunayevich et al., 2008) but this has not yet led to
an approved drug. Clearly, the importance of understanding the
role of mGlu2 receptors in physiology and pathology cannot be
overstated.
One of the issues has been that orthosteric agonists and an-
tagonists do not separate between mGlu2 and mGlu3 receptors
(Nicoletti et al., 2011), which have different, and possibly opposing
effects (Corti et al., 2007). To overcome this problem we recently
used a new selective mGlu2 receptor agonist, LY395756, and its
active enantiomer, LY541850 (Dominguez et al., 2005), to separate
between the roles of mGlu2 andmGlu3 receptors in synaptic events
(Ceolin et al., 2011; Hanna et al., 2013). However we found that
many of the outbred Wistar rats studied were unresponsive to the
selective mGlu2 agonist; this apparent anomaly was traced using
Western blotting to the lack of mGlu2 receptor expression in some
Wistar rats (Ceolin et al., 2011). Such animals being used for animal
modeling of human diseases clearly produce misleading results
when studying the roles of mGlu2 receptors. For example, mGlu2/3
agonists, known to reduce the phencyclidine-induced hyper-
locomotion in other rat strains (Moghaddam and Adams, 1998;
Cartmell et al., 2000; Monn et al., 2007), do not show this effect
in Wistar rats lacking mGlu2 receptors (Wood et al., 2014).
Because of the demonstrated potential of the mGlu2 receptor as
a therapeutic target, this ﬁnding is of critical importance to the
research community. Immediately questions arise as to i) why is the
mGlu2 receptor missing from some rats and ii) how frequently does
this occur in populations of rats used in laboratory studies. We
report here the occurrence of a single point mutation in exon 3 of
the Grm2 gene, which results in a premature stop codon at cysteine
407 of the mGlu2 receptor, and resultant loss of functional protein
expression. We also report the high frequency of this mutant ge-
notype in certain outbred and inbred rat lines that are commer-
cially available or selectively bred, and we discuss its inﬂuence on
behavioural characteristics.
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2. Methods
2.1. Animals
For the initial studies, Wistar rats from Banting & Kingman Ltd.
(UK), Harlan Laboratories (UK) and Charles River Laboratories (UK),
were housed in pairs under temperature controlled conditions in
standard laboratory housing. Experiments were conducted in
accordance with the Animals (Scientiﬁc Procedures) Act 1986 and
approved by local ethical review (University of Bristol). Sources,
and derivation details where appropriate, of animals used in the
genotyping survey are given in the Results section and in
Tables 1e3.
2.2. Initial investigation
Brieﬂy, spare hippocampal slices from rats determined electro-
physiologically to be sensitive or insensitive to a selective mGlu2
receptor agonist (see Mercier et al. (2013) for Methods) were frozen
at 80 C and RNA subsequently extracted using Qiagen RNeasy kit
according to the manufacturer's protocol. A ﬁrst strand synthesis
was performed using SuperScript III First Strand Synthesis Super-
mix (ThermoFisher Scientiﬁc) with Oligo(dT) according to the
manufacturer's protocol. cDNAwere then kept at20 C before PCR
ampliﬁcation. Initially, four pairs (A-D) of custom DNA oligonu-
cleotides were originally designed to cover most of Grm2 mRNA
(NM 001105711.1), namely nucleotides 131-147 and 854-834 (A),
819-838 and 1430-1411 (B), 1419-1439 and 2166-2147 (C) and
2003-2023 and 2824-2805 (D). A ﬁfth pair of primers, 1142-1161
and 1733-1714 (E) was subsequently ordered. All PCR primers were
purchased from Sigma Aldrich (UK) and used to amplify the
appropriate stretches of hippocampal cDNA. Following 35 PCR cy-
cles and conﬁrmation of correct PCR ampliﬁcation by gel electro-
phoresis, the ampliﬁed cDNA was puriﬁed, prepared and sent to
Source Bioscience (UK) for Sanger sequencing with the same
primers. The sequencing data were analysed using CodonCode
Aligner (v5.1.5) and expressed as chromatograms for illustration
(Fig. 1B).
2.3. Subsequent genotyping
Following the initial discovery of the cys407* mutation, the
protocol for genotyping was reﬁned and focused on the stretch of
gDNA, containing the mutation, using the following primers: nu-
cleotides 1301-1320 and 1488-1469 (NM 001105711.1) included in
exon 3. With this PCR primer pair (F), the method described above
was used for genotyping tissue in a survey of other outbred and
inbred rat strains as indicated in Tables 1 and 2. To collect tissue
samples, rats were euthanized by equivalent of UK Schedule 1
methods or, where appropriate, gently restrained to collect ear or
tail tissue. Tissue was frozen at 80 C, packaged in dry ice and, as
necessary, shipped to the University of Bristol for gDNA preparation
and assaying as above, with gDNA extracted using Qiagen DNeasy
kit according to the manufacturer's protocol.
2.4. Allelic discrimination
In parallel with the above genotyping, allelic discriminationwas
used to detect the presence or absence of the same mutation in
several strains fromHarlan (now Envigo) Laboratories, Indianapolis
(see Table 1 for details of rat lines examined). All animal tissue
collection protocols used in this study were approved by the Envigo
IACUC. Ear pinnae of approximately 2mmwere collected from each
animal tested and shipped frozen overnight to the Envigo genetic
testing services laboratory, located at the Bionomics and Research
Technology Center (BRTC) in Piscataway, New Jersey. SNP geno-
types were determined using Taqman chemistry with probes and
primers designed using Primer Express v.3.0. Primer sequences
include: Forward Primer: TGCCCTCTGTCCCAACAC; Reverse Primer:
GCGGCGCCCATTGAC; Reporter 1: TAGCATCGCAGAGGTG; Reporter
2: CATAGCATCTCAGAGGTG. Speciﬁc PCR cycling conditions are as
follows: 95 C, 10 min; (95 C, 30 s; 60 C, 1 min) x 40. Data were
collected upon completion of PCR ampliﬁcation in an end plate read
protocol and were analysed using ABI Fluidigm ViiA7 Real-Time
PCR System.
2.5. Western blot
To assess the endogenous expression of mGlu2 receptor protein
in mutant and wild-type rats, western blotting was performedwith
mGlu2 KO mouse tissue as a negative control (Fig. 1C). Cortical
tissues were lysed by RIPA buffer (50mM Tris-HCl (pH 6.8),150mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 0.5% SDS, 0.25% Na-
deoxycholate, 1  protease & phosphatase inhibitor cocktail (Cell
Signaling)) and immobilized on the PVDF membrane (Millipore,
IPVH00100). The mGlu2 receptor antibody (Millipore, 07-261-I,
1:1000) and alpha-tubulin antibody (Cell Signaling, #3873,
1:10,000) were used as primary antibodies.
2.6. Rat Genome Database (RGD) analysis
Prevalence analysis of the cys407* mutation was conducted
within rat strains contained in the RGD. Rat strains containing
variant informationwere analysed using the Variant Visualizer tool
(http://rgd.mcw.edu/rgdweb/front/conﬁg.html) and the Genome
Database browser (http://rgd.mcw.edu/jbrowse). Observation of
nonsense mutations within the Grm2 gene (Rn5; RGSC Rnor_5.0) at
chromosome 8, nucleotide 114,712,836 are reported.
3. Results
3.1. Discovery of the cys407* mutation in Grm2
Hippocampal cDNA from 3 B&KWistars (Bkl:WI), ‘insensitive’ to
the selective mGlu2 receptor agonist, LY541850, deﬁned electro-
physiologically (Mercier et al., 2013), and 1 ‘sensitive’ control
Charles River Wistar (Crl:WI) was sequenced using the 4 pairs of
initial primers (A-D). These provided nucleotide sequencing from
nt 141-843 (A), 829-1417 (B), 1432-2153 (C) and 2013-2814 (D) and
indicated no mutations within the Grm2 cDNA. The small uncov-
ered stretch of DNA from 1417 to 1432was subsequently sequenced
using primer pair E and the resultant Sanger chromatograms for all
3 ‘insensitive’ Wistar rats showed a single point mutation at nt1419
in exon 3; a cytosine was replaced by an adenine resulting in a stop
codon (TGA) rather than the codon (TGC) for cysteine at amino acid
407 of the mGlu2 receptor protein (Fig. 1). No other mutations
within the Grm2 gene were observed in any of the 4 rats. The
presence of the cys407* mutation was subsequently conﬁrmed
with the primer pair F using other tissue samples, deﬁned elec-
trophysiogically with LY541850 (Mercier et al., 2013). Such a pre-
mature stop codon provides the explanation for the absence of
protein as conﬁrmed by Western blotting (Fig. 1C) and hence the
lack of effect of a selective mGlu2 receptor agonist in some Wistar
rats (Ceolin et al., 2011). This mutation is the same as reported
independently in the Wistar-derived alcohol-preferring P rats
(Zhou et al., 2013).
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3.2. Prevalence of the mutation in commercially available Wistar
rats
To assist in the assessment of the frequency of the Grm2 cys407*
mutation in commercially available stocks of Wistar rats, tissue
samples from laboratory animal suppliers were genotyped. We
initially found that 100% of B&K Wistars (Bkl:WI) and Harlan HSD
Han Wistars (HsdHan:WIST) were 100% homozygous mutants
whereas 100% of Charles River Wistars (Crl:WI) were 100% homo-
zygous wild-type (Table 1). The survey was extended to other
Fig. 1. Discovery of the cys407* mutation within the Grm2 gene and loss of mGlu2 receptor expression in Han Wistar rats. (A) Structure of mGlu2 receptor cDNA showing the
regions mapped by ﬁve speciﬁc primers (A-E) used for Sanger sequencing. The site of the nonsense mutation at nt1419, results in a stop codon at cysteine 407, and is indicated on
both the cDNA and protein. (B) Typical Grm2wild type (TGC) and mutant (TGA) chromatograms from Sanger sequencing; arrows indicating the mutation site at nt1419. (C) Western
blots indicating the loss of mGlu2 receptor protein in homozygous cys407* mutant rats (Mut); the blots from mGlu2/ mice and wild type mice demonstrate the speciﬁcity of the
antibody. a-tubulin was used as a loading control.
Table 1
In-housegenotypicanalysis for theGrm2cys407*allele inrat lines fromcommercial suppliers.GenotypingwasconductedusingSangersequencingorallelicdiscrimination,with the
latter indicated by 1. Allelic frequency denotes frequencyof themutant cys407* allelewithin each sample. HanWistar sources used in the Palmet al., (2011a,b) studies are indicated
by 2. Furthermore, the following 14 inbred strains fromHarlan Labs (USA)were analysed by allelic discrimination and allwere homozygouswild type: ACI/Seg, LEW/SsNHsd, F344/
NHsd, WKY/NHsd, BN/SsNHsd, LE/CpbHsd, SHR/NHsd, SS/JrHsd, SR/JrHsd, LEW/HanHsd, BN/RijHsd, F344/NHsd, WF/NHsd (n¼ 5 per strain) and HsdCpb:WU (n¼ 80).
Commercial supplier Common name Nomenclature N Genotypic outcome Allelic frequency
Banting & Kingman (UK) B&K Wistar Bkl:WI2 14 100% mutant 1.0
Scanbur
(Sweden)
Scanbur B&K Wistar Sca:WI 9 45% mutant 0.61
33% hetero
22% wild type
Harlan Labs. (UK) HSD Han Wistar HsdHan:WIST 50 100% mutant 1.0
Harlan Labs. (UK) RCC Han Wistar HsdRcc:WIST 6 83% mutant 0.92
17% hetero
Harlan Labs. (USA)1 HSD Han Wistar HsdHan:WIST 50 100% mutant 1.0
Harlan Labs. (USA)1 RCC Han Wistar HsdRcc:WIST 50 98% mutant 0.99
2% hetero
Harlan Labs (Israel) HSD Han Wistar HsdHan:WIST 18 100% mutant 1.0
Harlan Labs (Netherlands) RCC Han Wistar HsdRcc:WIST2 6 67% mutant 0.83
33% hetero
Harlan Labs (USA) Harlan Wistar Hsd:WI 48 100% wild type 0.0
Harlan Labs (Israel) Harlan Wistar HsdOla:WI 48 100% mutant 1.0
Harlan Labs (USA)1 Sprague Dawley Hsd:Sprague Dawley 96 100% wild type 0.0
Harlan Labs (USA)1 Dark Agouti DA/OlaHsd 32 100% mutant 1.0
Charles River (UK) CR Wistar Crl:WI 50 100% wild type 0.0
Charles River (Germany) CR Wistar Crl:WI 10 50% wild type 0.25
50% hetero
Charles River (UK) CR Han Wistar Crl:WI(Han) 20 60% hetero 0.48
35% mutant
5% wild type
Charles River (UK) Wistar Kyoto WKY/NCrl 5 100% wild type 0.0
Charles River (France) CR Han Wistar Crl:WI(Han) 20 40% mutant 0.48
55% hetero
5% wild type
Taconic Farms (Denmark) Taconic Han Wistar HanTac:WH2 15 73% mutant 0.87
27% hetero
Janvier (France) Janvier Han Wistar RjHan:WI 10 60% hetero 0.3
40% wild type
Janvier (France) Janvier Dark Agouti DA/HanRj 10 100% mutant 1.0
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Wistar strains in Europe, the United States and Israel. A simple scan
of the data in Table 1 shows that Han Wistars, including RCC Han
Wistars (HsdRcc:WIST), are largely homozygous or heterozygous
mutants whereas Wistars without the ‘Han’ designation are pri-
marily wild-type, with the apparent exceptions of Harlan HsdOla
Wistars (HsdOla:WI) and the two B&K Wistar lines (Table 1). The
B&K Wistars are, however, known to be derived via the Hannover
Institute (Ceolin et al., 2011; Palm et al., 2011a, Fig. 2) and hence
these lines can be classiﬁed as Han Wistars.
Two non-Wistar lines in our survey of commercial sub-strains
showed the cys407* mutation, namely the Dark Agouti lines, DA/
OlaHsd and DA/HanRj (Table 1). A list of other inbred commercial
lines that did not carry the mutation is presented in the legend to
Table 1.
3.3. Prevalence of the mutation in rat lines selectively bred for
particular behavioural characteristics
Because some commercial outbred Wistars lacking expression
of mGlu2 receptors (Table 1) have been reported to have an
anxiety-like phenotype (Ceolin et al., 2011) and an increased
voluntary alcohol intake and riskerelated behaviours (Palm et al.,
Fig. 2. Dendrogram showing simpliﬁed scheme of derivation of commercial strains of Wistar, Han Wistar and Dark Agouti rats. For simpliﬁcation, the complex pathway
between the Wistar and Hannover Institutes, which included Glaxo (UK) Ltd, ICI (UK) Ltd and Allington Farms, Porton Down is abbreviated to ‘Several UK Establishments’. Modiﬁed
from IFFA Credo Ltd. scheme (Charles River Ltd.). The ﬁgures in parenthesis represent the allelic frequency for each commercial strain.
Table 2
Prevalence analysis for the Grm2 cys407* allele in rat lines selectively bred for particular behavioural characteristics. Genotypic outcome and cys407* mutant allele frequency
have been calculated for each rat line. Sources of the tissue for in-house genotyping are shown, with previously published genotyping data indicated by #.
Common name Nomenclature Source N Genotypic outcome Allelic frequency
Roman High Avoidance RHA-I Autonoma University, Barcelona, Spain 6 100% mutant 1.0
Roman Low Avoidance RLA-I 6 100% wild type 0.0
Alko Alcohol-Preferring AA National Institute for Health and Welfare, Helsinki, Finland 12 92% wild type 0.04
8% hetero.
Alko Non Alcohol-Preferring ANA 12 100% wild type 0.0
General Absence Epilepsy GAERS Grenoble Institut des Neurosciences, France 6 100% wild type 0.0
Non-Epileptic Control NEC 6 100% wild type 0.0
Alcohol Preferring# P Zhou et al. (2013)# 125 100% mutant 1.0
Alcohol Non-Preferring# NP NIAAA, NIH 59 100% wild type 0.0
Warsaw Alcohol High-Preferring WHP Institute of Psychiatry and Neurology, Warsaw, Poland 5 60% hetero. 0.5
20% mutant
20% wild type
Warsaw Alcohol Low-Preferring WLP 5 80% hetero. 0.4
20% wild type
Sardinian Alcohol Preferring sP University of Cagliari, Sardinia 10 50% hetero. 0.65
40% mutant
10% wild type
Sardinian Alcohol Non-Preferring sNP 10 100% wild type 0.0
High Anxiety-related Behaviour HAB University of Regensburg, Germany 8 100% mutant 1.0
Low Anxiety-related Behaviour LAB 9 100% mutant 1.0
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2011a, 2011b; Momeni et al., 2015), we extended the investigation
of the cys407* mutation prevalence to small cohorts from lines
selectively bred for particular behavioural phenotypes (Table 2).
The Wistar-derived Roman High- (RHA) and Low-Avoidance
(RLA) rat lines were initially selected and outbred in Rome on the
basis, respectively, of their good or poor acquisition of the two-way
active avoidance response (Bignami, 1965) and transferred to Zür-
ich in 1972 (Driscoll and B€attig, 1982; Driscoll et al., 1998; Steimer
and Driscoll, 2003). From these RHA/Verh and RLA/Verh lines,
two inbred lines (RHA-I and RLA-I) were derived and maintained at
the Autonomous University of Barcelona since 1997 (Escorihuela
et al., 1999; Driscoll et al., 2009). Analysis of samples from 6 RHA-
I and 6 RLA-I male rats showed that all RHA-I rats and no RLA-I
rats from Barcelona expressed the mutation (Table 2).
The Alko Alcohol-preferring (AA) and Alko Non Alcohol-
preferring (ANA) rats were derived from a Wistar-Sprague Daw-
ley cross in the 1960s (Eriksson, 1968). Other non-Wistar strains
were bred into them for further selective breeding for alcohol
preference (Hyytia et al., 1987; Sommer et al., 2006). On genotyping
the AA and ANA rats (n ¼ 12/strain), all were wild-type, except for
one AA rat, which was heterozygous for the cys407* allele (Table 2).
Generalized Absence Epilepsy Rats from Strasbourg (GAERS)
were selectively bred for spontaneous absence seizures from a 20-
year old in-house Wistar stock in the early 1980s (Vergnes et al.,
1982; Marescaux and Vergnes, 1995; Danober et al., 1998).
Neither the GAERS samples (n ¼ 6) nor the non-epileptic control
rats (NEC; n ¼ 6) contained the cys407* mutation (Table 2).
In the early 1990s in Munich, Wistar rats from Charles River
(Germany) were selectively bred, based on their behaviour in the
elevated plus-maze into two lines, one with High Anxiety-related
Behaviours (HAB) and the other with Low Anxiety-related Behav-
iours (LAB; Liebsch et al., 1998). The initial HAB and LAB lines were
crossed with other Wistar (Wis/Prob) rats selectively bred in
Leipzig for low and high performance respectively in a
shockemotivated brightness discrimination task (Hess et al., 1992).
The resulting HAB and LAB breeding lines, currently maintained at
the University of Regensburg, showmany signs of clinical anxiety as
well as abnormal aggressive behaviour (Landgraf and Wigger,
2002; Neumann et al., 2010). When genotyped for the Grm2 mu-
tation, all HAB (n ¼ 8) and LAB (n ¼ 7) rats, veriﬁed individually for
their respective anxiety-like characteristics using the elevated plus
maze, were homozygous for the cys407* mutation (Table 2).
The Sardinian alcohol-Preferring (sP) and alcohol Non-
Preferring (sNP) lines were developed through a selective
outbreeding program starting from a stock of Wistar rats bred at
Morini, San Polo d’Enza, Italy (see Colombo et al., 2006). The sP rats
display increased anxiety-related behaviours relative to sNP rats
(Colombo et al., 1995; Roman and Colombo, 2009). When geno-
typed, the sP (n ¼ 10) and sNP (n ¼ 10) rats were clearly
distinguished between lines with Grm2 cys407* alleles only in the
alcohol-preferring line, with no mutants in the sNP line (Table 2).
Similarly the selective breeding of Warsaw High alcohol-
Preferring (WHP) and Low alcohol-Preferring (WLP) rats was
commenced in the early 1990s from Wistar stock (Bisaga and
Kostowski, 1993; Dyr and Kostowski, 2004). The WHP rats display
lower anxiety-related and depressive-like behaviours than theWLP
rats (Acewicz et al., 2014). Unlike many of the above lines selec-
tively bred for alcohol intake, the WHP rats (n ¼ 5) and WLP rats
(n ¼ 5) were similar in Grm2 genotype, with both lines showing a
mixture of Grm2 mutants and wild types (Table 2).
Examination of the Rat Genome Database (RGD) for the cys407*
mutation revealed this mutation in a number of inbred lines
(Table 3), including another Dark Agouti line (DA/BklArbNsi) and
the Maudsley Reactive line (MR/N; Broadhurst 1975; Blizard et al.,
2015). TheseMR/N rats were bred fromWistars on the basis of rates
of defaecation in an open ﬁeld setting, the inbred strain in the RGD
being homozygous for the Grm2 mutation. On this database of 43
inbred strains, there were 9 rat lines expressing the mutation. Four
of these mutant lines, BUF/N, M520, WN/N and MR/N itself, were
used to derive the N/NIH heterogeneous stock rats from a total of 8
lines (Hansen and Spuhler, 1984).
4. Discussion
Our independent ﬁnding of the cys407* mutation in Grm2 (re-
ported here), the description of the cys407* mutation in alcohol-
preferring P rats (Zhou et al., 2013), and the low mGlu2 receptor
expression in inbred Roman High Avoidance (RHA-I) Wistar-
derived rats (Klein et al., 2014) demanded a widespread survey
for this Grm2 mutation among Wistar rats. This has led us to
discover a preponderance of the cys407* mutation in some com-
mercial Wistar rats and in some selectively bred lines of Wistar
origin (Tables 1e3). The discussion will focus on the discovery,
prevalence and origin of the mutant genotype and the implications
for use in neuroscience research. We also consider how this mu-
tation may relate to a speciﬁc behavioural phenotype.
4.1. Discovery, prevalence and origin of the cys407* mutation
In addition to our own observation that some strains of Wistar
rats have reduced expression of the mGlu2 receptor (Ceolin et al.,
2011), others have made similar observations, noting only silent
mutations, reductions in transcript level and potential epigenetic
changes (Lindemann et al., 2006; Klein et al., 2014). The molecular
basis for the reduced mGlu2 receptor expression was not deter-
mined until our discovery (April 2013) of the cys407*mutation and,
independently reported by Zhou et al. (2013) in the Wistar-derived
P rats, a line selectively bred for alcohol consumption and
Table 3
Results showing rat lines that contain the Grm2 cys407* allele from the Rat Genome Database (RGD) using the Variant Visualizer tool (http://rgd.mcw.edu/rgdweb/front/conﬁg.
html). All lines listed are homozygous for themutant Grm2 allele. The code and RGD ID for each rat line are indicated. The variant data resources include The Royal Netherlands
Academy of Arts and Sciences (KNAW), Medical College of Wisconsin (MCW), National Institute of Health (NIH) and Atanur et al. (2013). * Indicates the 4 rat lines of the 8 used
to breed the N/NIH heterogeneous stock rats.
Common name Nomenclature RGD ID Data resource Variant ID
Biobreeding rats BBDP/WorN 1598798 KNAW 588304182
Buffalo rats BUF/N* 60986 KNAW 591803679
Dark Agouti rats DA/BklArbNsi 1600340 KNAW 595199597
Marshall 520 rats M520/N* 10024 KNAW 631632754
Maudsley Reactive rats MR/N* 70449 KNAW 565287345
Milan Normotensive rats MNS/Gib 10028 KNAW 634892321
Sabra Hypotension resistant SBN 68130 MCW 532608734
Sabra Hypotension resistant SBN/Ygl 631573 KNAW 641705586
Inbred Wistar NIH WN/N* 10045 NIH 548665674
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preference (Lumeng et al., 1977; Li et al., 1979). Building on this
work, we have now surveyed a number of commercially available
Wistar stocks including those used for behavioural proﬁling and
assessment of voluntary alcohol intake (Palm et al., 2011a,b
Momeni et al., 2015) and a few selectively-bred lines showing
phenotypes that tentatively might be linked to loss of mGlu2 re-
ceptors. Lastly, we have interrogated the Rat Genome Database to
further explore the prevalence of the Grm2 cys407* mutation.
Our data show widespread distribution of the cys407* mutation
in commercially available Wistar rats of different origin and from
different suppliers (Table 1), particularly those with known his-
torical derivation from the Hannover Institute (Zentral Institut fur
Versuchstierzucht; Fig. 2). This may provide a clue to the origin of
the mutation. Founders from the Hannover Institute were distrib-
uted to inter alia IFFA-Credo (later Charles River, France), Biomed-
ical Research Laboratories (BRL; later Research Consulting
Company, RCC; Switzerland) and Bury Green Farm (Glaxo, UK).
These were the sources, which have given rise to commercial Han
Wistar colonies expressing the cys407* mutation (Fig. 2). It can
therefore be assumed that the mutation was common within the
Wistar stock at the Hannover Institute. At ﬁrst sight, it seems likely
that the initial spontaneous mutation occurred at the Hannover
Institute presumably in a single animal. An earlier event, e.g. at an
establishment in the UK or even at the Wistar Institute itself (see
Fig. 2) is, however, perhaps more likely; a small number of resultant
mutants then being chosen by chance to act as founders at the
Hannover Institute. Similarly, although Wistar rats from commer-
cial stocks not originating via the Hannover Institute generally do
not appear to contain the mutation (see Fig. 2; Tables 1 and 2),
presence of the mutation in the Harlan Wistar (HsdOla:WI) and in
some older inbred lines in the Rat Genome Database, including the
Maudsley Reactive line (MR/N; Table 3) also suggests a pre-
Hannover event. The non-Wistar Dark Agouti rats (DA/OlaHsd,
DA/HanRj and DA/BklArbNsi) were surprisingly all homozygous
cys407* mutants. Unfortunately, tracing the precise origins of many
of these older lines is virtually impossible and so a Han Wistar
lineage could not be determined, e.g. (http://www.informatics.jax.
org/external/festing/rat/docs/DA.shtml).
Selective breeding for a particular behavioural trait from stock
containing some mutants may lead to a change in frequency of the
407* mutation, if this allele inﬂuences the sought for phenotype
(see below). Why, however, did loss of the mGlu2 receptor result in
such rats becoming the most numerous genotype in some com-
mercial colonies? Was it just by chance that the rats used as
founders or for revitalizing some colonies were mostly Grm2
mutant rats or does the mutation provide some phenotypic
advantage in commercial breeding laboratories? Obvious expla-
nations might be that cys407* mutant rats are more efﬁcient in
terms of growth or fecundity. Something as simple as handling
characteristics or interactionwith humans may also affect choice of
individual rats for breeding in establishments where no phenotype
is actively sought. Further behavioural studies comparing ‘Han’ and
‘non-Han’ lines of Wistar rats (e.g. Palm et al., 2011a) may even-
tually disclose some as yet unknown characteristic, which leads to
Grm2 mutant individuals being chosen for breeding.
In addition to evidence of a prevalence of the mutation in
outbred stocks of Wistar rats of Han origin, we have also shown
Grm2 genotypic heterogeneity between certain selectively bred
lines. This raises the possibility that the presence of speciﬁc
behavioural characteristic, e.g. alcohol preference, may be linked to
the expression of mGlu2 receptors and thus selection of animals for
such behaviours will result in lines with different prevalence of the
mutation. In particular, the link between the Grm2 mutation,
alcohol intake, anxiety-related and risk-related behaviours are of
particular interest and are discussed in more detail below.
4.2. Behavioural characteristics of sub-strains lacking mGlu2
receptors
In addition to the electrophysiological differences noted with
selective mGlu2 receptor agonists (Ceolin et al., 2011; Hanna et al.,
2013; Lucas et al., 2013; Mercier et al., 2013; Sanger et al., 2013),
differences in behaviours related to emotionality were also
observed (Bert et al., 2001; Ceolin et al., 2011; Palm et al., 2011a;
Honndorf et al., 2011). When tested in the multivariate concentric
square ﬁeld™ test (MCSF), the main segregating factors for the Han
Wistar rats were lower general activity but increased activity in
areas associated with risk, i.e. higher risk taking behaviour (Palm
et al., 2011a). With the knowledge of distribution of the cys407*
mutation in the rat strains from Table 1, this behavioural correlation
with genotype can be illustrated (Fig. 3). Whilst this provides an
interesting insight into the potential link between the mutation
and behavioural characteristics, it should be noted that most
studies have only examined a small number of strains and there is
considerable behavioural variation depending on the task used and
comparison groups (Palm et al., 2011a; Goepfrich et al., 2013;
Momeni et al., 2015).
Among lines selected for behavioural phenotype, the RHA-I rats
(homozygous for the cys407*mutation) were originally selected for
breeding based on rapid acquisition of avoidance responses in
shuttle boxes (Bignami, 1965; Driscoll and B€attig, 1982; Driscoll
et al., 1998; Escorihuela et al., 1999). The fact that only 5 genera-
tions were needed to establish this phenotype (Bignami, 1965)
suggests relatively high penetrance of the genotype. The RHA-I rats
show aspects of impulsivity, risk-taking and sensation seeking
(Escorihuela et al., 1999; Lopez-Aumatell et al., 2009a; Moreno
et al., 2010; Klein et al., 2014), characteristics which have some
parallels with the behavioural phenotype reported in commercially
available Han Wistars (Palm et al., 2011a; Momeni et al., 2015).
Whilst the distribution of the Grm2 mutation within different
outbred Wistar populations cannot be speciﬁcally linked to
emotional behaviour, there is some evidence to suggest anxiety-
related behaviour in mutant versus non-mutant animals (Ceolin
et al., 2011) or risk/impulsivity-related behaviours (Palm et al.,
2011a; Klein et al., 2014). However, whilst the Grm2 mutation will
have particular inﬂuences on behaviour, differences in the methods
used to study these behaviours (Steimer and Driscoll, 2003; Diaz-
Moran et al., 2012; Klein et al., 2014) and other genetic and envi-
ronmental/experimental features will overlay and complicate
interpretation.
4.3. Alcohol intake in sub-strains lacking mGlu2 receptors
Wistar rats from commercial sub-strains lacking the mGlu2
receptor tend to consume more alcohol than non-Han Wistar rats
(Palm et al., 2011b). However, there are inconsistencies in the data
relative to our analysis of the prevalence of the mutation. Low
voluntary alcohol intake was observed in the B&K Wistar rats
(Bkl:WI; Palm et al., 2011b), and the Taconic Han Wistar (Han-
Tac:WH) consumed less alcohol compared to the RCC Han Wistar
(RccHan:WI; Palm et al., 2011b; Momeni et al., 2015) with
RccHan:WI consuming more alcohol than other Wistar rats of Han
origin (Goepfrich et al., 2013). This anomaly of low alcohol intake in
B&K Wistar rats, which showed heterogeneity in frequency of the
Grm2 mutation between suppliers (Table 1), unfortunately cannot
be conﬁrmed because this source of rats is no longer available.
Adding to the case for a link between alcohol intake and the
mutation, alcohol-preferring P but not non-preferring NP rats,
selectively bred from aWistar colony held at theWalter Reed Army
Hospital (Lumeng et al., 1977) were homozygous for the cys407*
mutation (Zhou et al., 2013). Likewise, the RHA-I but not RLA-I rats
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are also homozygous for the cys407* mutation and RHA-I rats have
a higher alcohol intake that the RLA-I rats (Manzo et al., 2012;
Corda et al., 2014). However, unlike the alcohol-preferring P and
RHA-I rats, the Helsinki alcohol-preferring AA (Sommer et al.,
2006) have few mutant alleles (Table 2). Therefore segregation
between the two lines, and any inﬂuence of the Grm2 mutation on
the alcohol drinking characteristic cannot be determined from the
AA/ANA lines.
By contrast to the AA/ANA lines, the Warsaw alcohol High-
Preferring (WHP) and Low-Preferring (WLP) rats, which were also
selectively bred from Wistar stock (see Dyr and Kostowski, 2004),
did have a high proportion of cys407*mutant alleles. However, they
could not be differentiated with respect to the Grm2mutation, with
the distribution of the cys407* allele being similar in bothWHP and
WLP lines (Table 2). But supporting the link between alcohol intake
and lack of the mGlu2 receptor, the Sardinian alcohol-Preferring sP
and alcohol Non-Preferring sNP rat lines initiated fromWistar stock
in 1981 (see Colombo et al., 2006) were clearly distinguished by
genotype, the mutant allele being found only in the alcohol-
preferring sP line (Table 2).
Thus, despite the anomaly with the B&K and Warsaw rats (see
above), these ﬁndings strongly support the hypothesis that lack of
the mGlu2 receptor contributes to alcohol intake, but is not a
requirement (Zhou et al., 2013). Another important pair of selec-
tively bred lines, the high and low alcohol drinking rats (HAD and
LAD respectively; Li et al., 1993) have not yet been genotyped. These
rats were selectively bred from the N/NIH heterogeneous stock,
which in turn were produced by crossing 8 inbred sub-strains,
many with some Wistar lineage (Hansen and Spuhler, 1984; Bell
et al., 2012), 4 of which were Grm2 mutants (see Table 3). Inter-
estingly the 4 Grm2 mutant lines (BUF/N, M520, WN/N and MR/N)
were in the top 5 of the 8 N/NIH founders for alcohol preference
and consumption (Spuhler and Dietrich, 1984). Our hypothesis
above suggests that the mutant cys407* alleles from 4 of the
founders will, on selection for alcohol consumption, segregate in
the HAD rather than the LAD line. Note added in revision: Indeed,
HADs have a cys407* mutant allelic frequency of 0.87 versus the 0.5
presumed for the original N/NIH stock (Professor Bill
Muirepersonal communication).
This hypothesis is also supported by pharmacological data in
which mGlu2/3 receptor agonists reduce self-administration in
mGlu2-competent rats (Backstrom and Hyytia, 2005) but not in
mGlu2-deﬁcient P rats (Rodd et al., 2006). Surprisingly, activation
of these receptors did reduce alcohol-seeking behaviour of P rats in
the latter study (Rodd et al., 2006). In addition, agonists of mGlu2/3
receptors block the discriminative stimulus effects of alcohol in
non-Wistar rats (Cannady et al., 2011) and alcohol seeking behav-
iour (Besheer et al., 2010). Such data are in agreement with a large
body of literature suggesting thatmGlu2/3 agonists reduce both the
rewarding value of drugs of abuse and the reinstatement of drug
seeking behaviour (Moussawi and Kalivas, 2010), most likely
because activation of mGlu2/3 receptors reduces dopamine release
in the nucleus accumbens shell (Greenslade and Mitchell, 2004;
Karasawa et al., 2006). Interestingly, P rats that contain the muta-
tion show a greater alcohol-induced accumbens dopamine
response than NP rats whereas there is little difference between AA
and ANA rats (Kiianmaa et al., 1995; Bell et al., 2012). Similarly the
RHA rats (Manzo et al., 2012) have a larger dopamine response to
alcohol than the RLA rats (Corda et al., 2014). These data support
the concept that activation of mGlu2 receptors limits the dopamine
response to alcohol and other drugs of abuse (see reviewMoussawi
and Kalivas, 2010; Kim et al., 2005; Liechti et al., 2007). Our present
data and inter alia increased cocaine responsiveness in mGlu2/
mice (Morishima et al., 2005) and in RHA rats (Giorgi et al., 2007)
indicate mGlu2 receptors as a therapeutic target in alcohol and
other drug use disorders.
Fig. 3. Principal component analysis (PCA) for individual Wistar rats from ﬁve different suppliers behaviourally proﬁled in the multivariate concentric square ﬁeld™ test. Modiﬁed
from Palm et al., (2011a) following the statistical guidelines for PCA analysis of Eriksson et al. (2006). For illustration purposes, the blue line circles the majority (15 of 19) of Wistar
rats of non-Han origin, and the red dotted line circles the majority (27 of 29) of Wistar rats of Han origin, i.e. those showing high prevalence for the Grm2 mutation.
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Because anxiety trait and alcohol use disorders have been linked
in humans (Morris et al., 2005; Helton and Lohoff, 2015; but see
Fein, 2015) and laboratory animals (Stewart et al., 1993; Spanagel
et al., 1995; Colombo et al., 1995), it is tempting to ascribe cause
and effect to these two aspects of animal behaviour. However, in-
dividual rat scores on these two phenotypes within a group of 60
RCC HanWistar rats were not associated. Instead rats with high risk
assessment behaviour displayed higher voluntary alcohol intake
(Momeni et al., 2014). Also, against the link between mGlu2 re-
ceptor deﬁcit, alcohol preference and anxiety trait is the evidence
from the RHA-I and RLA-I rats; the RHA-I rats have the Grm2 mu-
tation and consume more alcohol but show more aspects of
impulsivity, risk-taking and sensation-seeking than the RLA-I rats
(Escorihuela et al., 1999; Steimer and Driscoll, 2005; Lopez-
Aumatell et al., 2009b). Also, recently the alcohol-preferring P
rats (see below), which also have the cys407* mutation (Zhou et al.,
2013, Table 2), were found to be more risk-taking than their non-
preferring NP and mGlu2 receptor competent counterparts
(Roman et al., 2012) in contrast to a previous report suggesting an
anxious phenotype for P rats (Stewart et al., 1993). In an attempt to
pursue the potential link between the Grm2 mutation and anxiety
(Ceolin et al., 2011), samples from Wistar rats selectively bred for
high and low anxiety-related behaviours (HAB and LAB; see
Landgraf and Wigger, 2002) were genotyped. Unfortunately for
advancing this discussion, all the samples from both HAB and LAB
lines were homozygous for the mutation, suggesting that founders
came from Wistar stocks with a high percentage of Grm2 mutants.
Similarly, the epileptic GAERS line shows more anxiety-related
behaviours than the non-epileptic NEC line (Jones et al., 2008),
but does not contain the cys407* mutation.
4.4. Implications for use of cys407* mutant rats in neuroscience
research
Although clearly there are large genetic differences between rat
strains, the ﬁnding that the cys407* mutation of the Grm2 gene is
expressed as the more frequent allele in several commercially
available Wistar rat sub-strains is of major concern. The mGlu2
receptor is a key player in many aspects of synaptic transmission
and plasticity throughout the CNS (Yokoi et al., 1996; Mukherjee
and Manahan-Vaughan, 2013) and is widely regarded as an
important target for drug development for neurological and psy-
chiatric diseases (Niswender and Conn, 2010; Nicoletti et al., 2011;
Li et al., 2015). Clearly these mutant rats will give atypical results in
studies using mGlu2 receptor ligands.
Because many studies have been performed with agonists and
antagonists that do not separate between mGlu2 and mGlu3 re-
ceptors, both type 1 (an action via mGlu3 receptors may have been
ascribed to mGlu2 receptors) and type 2 (lack of effect due to
absence of the mGlu2 receptor) errors may have occurred. Pub-
lished examples are difﬁcult to ﬁnd because the strains of rats are
often not given in sufﬁcient detail and negative results are not al-
ways published. It is nevertheless very important that the preva-
lence of this mutation is recognized by scientists investigating the
role of mGlu2 and mGlu3 receptors both physiologically and
therapeutically.
By the same token, the cys407* mutation provides researchers
with a valuable tool to separate between functions of mGlu2 and
mGlu3 receptors, an issue that has slowed drug development in
this ﬁeld (Niswender and Conn, 2010; Nicoletti et al., 2011). As
mentioned above, some mGlu2/3 agonists have been withdrawn
from further development on the grounds of rat toxicity
(Dunayevich et al., 2008), the Han Wistar rats will allow the off-
target toxicity to be investigated in isolation. Knock-out mice are
available for investigating the inﬂuence of individual genes.
However, the majority of behavioural tests have been developed in
rats, which provide the bulk of rodent behavioural literature
(Hanell and Marklund, 2014). Hence, the cys407* mutant rats
provide a valuable resource for distinguishing between mGlu2 and
mGlu3 receptor functions. Thus the mutant Han Wistar sub-strains
provide the opportunity to study the role and therapeutic potential
of mGlu3 receptors in the absence of complicating data from
interaction of ligands with mGlu2 receptors. For example, the po-
tential for mGlu3 agonism in neuroprotection, although widely
appreciated (Bruno et al., 2001; Corti et al., 2007; Caraci et al., 2012;
Motolese et al., 2015), has yet to be fully developed and could be
more widely explored in these mutant rats.
4.5. General conclusion
Discovery of the cys407* mutation in Grm2 and its prevalence in
Wistar rat sub-strains originating from the Hannover Institute has
indicated the likely restraining inﬂuence of mGlu2 receptors in
animal models of alcohol use disorders in particular, and substance
use disorders in general. The data supports the therapeutic op-
portunity for mGlu2 receptor agonists in research on drug addic-
tion mechanisms and more generally for emotional, risk-related
and impulsive behaviours. Rat strains with this cys407* Grm2
mutation provide a useful model for understanding the separate
roles of mGlu2 and mGlu3 receptors in physiology and pathology.
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